Inflammatory responsive neutrophil-like membrane-based drug delivery system for post-surgical glioblastoma therapy.

J Control Release

The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China. Electronic address:

Published: October 2023

Surgical resection of glioblastoma (GBM) causes brain inflammation that activates and recruits neutrophils (NEs) to residual GBM tissues. NE-based drug delivery using inflammatory chemotaxis is promising for the post-surgical treatment of residual GBM, but its clinical application is limited by the short life span of NEs and lack of in vitro propagation methods. HL60 cells are a type of infinitely multiplying tumor cells that can be induced to differentiate into NE-like cells. We developed a novel NE-like membrane system (NM-PD) by coating NE-like membranes on the surface of poly (lactide-co-glycolide)-poly(ethylene glycol) (PLGA-PEG)-based doxorubicin (DOX)-loaded core (PLGA-PEG-DOX, PD) for post-surgical residual GBM treatment. Cell adhesion proteins were detected on NE-like membranes and endowed NM-PDs with inflammatory chemotaxis similar to mature NEs. The resulting NM-PD shows excellent inflamed in vitro blood-brain barrier (BBB) permeability and anti-proliferative effects on GBM cells. In our intracranial GBM resection model, NM-PD exhibited superior inflammatory chemotaxis and targeted residual GBM cells, thus remarkably improving antitumor capability and prolonging the survival time of the mice. These data suggest that NM-PD, which has sufficient sources and is easy to prepare, can efficiently suppress post-surgical residual GBM and holds potential for clinical transformation in GBM post-surgical adjuvant therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2023.08.020DOI Listing

Publication Analysis

Top Keywords

residual gbm
20
inflammatory chemotaxis
12
gbm
9
drug delivery
8
ne-like membranes
8
post-surgical residual
8
gbm cells
8
post-surgical
5
residual
5
cells
5

Similar Publications

An NIR-II Two-Photon Excitable AIE Photosensitizer for Precise and Efficient Treatment of Orthotopic Small-Size Glioblastoma.

Adv Mater

December 2024

School of Science and Engineering, Shenzhen Institute of Aggregate Science and Technology, The Chinese University of Hong Kong (CUHK-Shenzhen), Shenzhen, Guangdong, 518172, P. R. China.

The existence of residual small-size tumors after surgery is a major factor contributing to the high recurrence rate of glioblastoma (GBM). Conventional adjuvant therapeutics involving both chemotherapy and radiotherapy usually exhibit unsatisfactory efficacy and severe side effects. Recently, two-photon photodynamic therapy (TP-PDT), especially excited by the second near-infrared (NIR-II) light, offers an unprecedented opportunity to address this challenge, attributed to its combinational merits of PDT and TP excitation.

View Article and Find Full Text PDF

Survival quality of glioblastoma (GBM) patients remains undesirable despite the aggressive multimodal treatment methods implemented, which are strongly associated with tumor recurrence after surgical resection. Self-renewal and strong tumourigenic capacity of glioblastoma stem cells (GSCs) at the narrow margin of the incision are essential factors driving tumor secondary strikes. Currently, the challenges in treating postoperative residual GSCs are mainly due to the lack of materials for incision and GSCs targeting.

View Article and Find Full Text PDF
Article Synopsis
  • Glioblastoma (GBM) is the deadliest brain tumor in adults, and current therapies are largely ineffective, which drives the need for new treatment strategies based on the tumor's metabolic needs, specifically glucose and glutamine.
  • A ketogenic metabolic therapy (KMT) approach targets these metabolic pathways by combining dietary changes with specific drugs to limit glycolysis and glutaminolysis, while promoting the use of non-fermentable fuels like ketones and fatty acids.
  • The glucose-ketone index (GKI) serves as a biomarker to monitor treatment effectiveness, aiming to create a more hostile environment for tumor growth and improve outcomes in GBM as well as potentially other cancer types reliant on similar metabolic pathways.
View Article and Find Full Text PDF

Optimal timing of chemoradiation after resection or biopsy of glioblastomas: a nationwide population-based study.

BMC Cancer

November 2024

Department of Neurosurgery, Brain Tumor Center, Ajou University School of Medicine, Ajou University Hospital, 164 Worldcup-Ro, Yeongtong-Gu, Suwon, 16499, Republic of Korea.

Background: This study investigated the optimal timing of concurrent chemoradiotherapy (CCRT) following surgery for patients with newly diagnosed glioblastoma (GBM). The focus was on understanding whether the interval between surgery and CCRT impacts survival outcomes.

Methods: Data from the Korean National Health Insurance Research Database ( https://opendata.

View Article and Find Full Text PDF

Convection-enhanced delivery of [Lu]Lu-labeled gold nanoparticles combined with anti-PD1 checkpoint immunotherapy improves the survival of immunocompetent C57BL/6J mice with orthotopic GL261 murine glioma tumors.

Nucl Med Biol

November 2024

Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada; Department of Medical Imaging, University of Toronto, Toronto, ON, Canada; Laboratory Medicine Program, University Health Network, Toronto, ON, Canada. Electronic address:

Introduction: Our objective was to study convection enhanced delivery (CED) of Lu-labeled metal chelating polymer (MCP) conjugated to gold nanoparticles ([Lu]Lu-MCP-AuNP) alone or combined with anti-PD1 immune checkpoint inhibition (ICI) for improving the survival of immunocompetent C57BL/6J mice with orthotopic GL261 murine glioma tumors.

Methods: C57BL/6J mice with GL261 tumors were treated with [Lu]Lu-MCP-AuNP (0.8 or 2.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!